12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) is an effective cancer therapeutic reagent for myelocytic leukemia patients (Han et al., 1998), and MTURN is TPA‐responsive and may promote both leukemic and normal megakaryocyte differentiation (Sun et al., 2014). This evidence concerns the gene MTURN and myeloid leukemia.